We are live on ! Find out more
FPRX

Five Prime Therapeutics, Inc.
FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

125 hedge funds and large institutions have $664M invested in Five Prime Therapeutics, Inc. in 2020 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 41 increasing their positions, 25 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

433% more capital invested

Capital invested by funds: $125M → $664M (+$540M)

141% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 22

64% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 25

33% more funds holding

Funds holding: 94125 (+31)

3% more call options, than puts

Call options by funds: $4.63M | Put options by funds: $4.51M

Holders
125
Holders Change
+31
Holders Change %
+32.98%
% of All Funds
2.21%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
53
Increased
41
Reduced
25
Closed
22
Calls
$4.63M
Puts
$4.51M
Net Calls
+$122K
Net Calls Change
+$42K
Name Holding Trade Value Shares
Change
Change in
Stake
FCM
26
Farallon Capital Management
California
$6.8M +$5.01M +400,000 New
EAM
27
Erste Asset Management
Austria
$6.7M -$535K -42,726 -10%
Northern Trust
28
Northern Trust
Illinois
$6.59M +$440K +35,080 +10%
OM
29
Opaleye Management
Massachusetts
$6.5M +$4.78M +381,900 New
Millennium Management
30
Millennium Management
New York
$6.21M +$3.4M +271,026 +288%
Acadian Asset Management
31
Acadian Asset Management
Massachusetts
$6.09M -$3.54M -282,539 -44%
PPA
32
Parametric Portfolio Associates
Washington
$5.44M +$632K +50,462 +19%
Charles Schwab
33
Charles Schwab
California
$5.37M +$397K +31,716 +11%
APM
34
Avidity Partners Management
Texas
$5.1M +$3.76M +300,000 New
RPAM
35
Rhenman & Partners Asset Management
Sweden
$4.25M +$3.13M +250,000 New
VA
36
VR Adviser
New York
$4.17M +$3.07M +245,122 New
PIM
37
Platinum Investment Management
Australia
$4.1M -$1.08M -86,171 -26%
Assenagon Asset Management
38
Assenagon Asset Management
Luxembourg
$3.87M -$3.76M -300,406 -57%
Goldman Sachs
39
Goldman Sachs
New York
$3.84M +$864K +68,962 +44%
Alyeska Investment Group
40
Alyeska Investment Group
Illinois
$3.57M +$2.63M +209,691 New
EP
41
Eversept Partners
New York
$3.56M +$2.62M +209,155 New
Bank of New York Mellon
42
Bank of New York Mellon
New York
$2.96M +$657K +52,443 +43%
JP Morgan Chase
43
JP Morgan Chase
New York
$2.87M -$426K -33,967 -17%
AGA
44
Altrinsic Global Advisors
Connecticut
$2.76M +$902K +72,000 +80%
EI
45
EAM Investors
California
$2.28M +$1.68M +134,162 New
BCM
46
Bridgeway Capital Management
Texas
$2.24M
N
47
Nuveen
North Carolina
$2.21M +$3.12M +249,136 +152%
Macquarie Group
48
Macquarie Group
Australia
$1.7M
HM
49
HealthCor Management
New York
$1.48M +$1.09M +86,930 New
EGI
50
EAM Global Investors
California
$1.37M +$1.01M +80,669 New

FPRX Hedge Fund Activity: Q4 2020 in Review

125 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q4 2020, worth a combined $664M — up 433% from $125M a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new FPRX positions and 22 closed out — a net gain of 31 holders — while 41 added to existing stakes and 25 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $53.7M. The largest seller was BVF Inc, cutting an estimated $87.3M.

  • 125 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q4 2020, up from 94 in Q3 2020.
  • Funds reported $664M of Five Prime Therapeutics, Inc. stock for Q4 2020, up 433% quarter-over-quarter.
  • 53 funds opened new Five Prime Therapeutics, Inc. positions in Q4 2020 and 22 closed out, a net change of +31 holders.
  • The largest Five Prime Therapeutics, Inc. buyer in Q4 2020 was RA Capital Management, an estimated $53.7M added.
  • The largest Five Prime Therapeutics, Inc. seller in Q4 2020 was BVF Inc, an estimated $87.3M sold.

Based on aggregated 13F filings for Q4 2020.